Cholecystectomy in patients with hematologic malignancies

Am J Surg. 2022 Jun;223(6):1157-1161. doi: 10.1016/j.amjsurg.2021.10.037. Epub 2021 Oct 24.

Abstract

Background: Cholecystectomy in patients with hematologic malignancies remains poorly understood.

Methods: We retrospectively evaluated patients with hematologic malignancies who underwent cholecystectomy at a single institution.

Results: Of 313 patients who presented for evaluation of abdominal pain, 64 underwent cholecystectomy for acute cholecystitis (34.4%), gangrenous cholecystitis (21.9%), chronic cholecystitis (23.4%), and cholelithiasis (20%). Most had a history of hematopoietic cell transplantation (62.5%) and/or immunosuppressive medication within 30 days of consultation (82.8%). Ultrasound had a 39% false-negative rate for acute nongangrenous cholecystitis. Operative time was 92 ± 39 min, 7 were performed open, 10 had intraoperative transfusions, and 4 had grade 3+ complications. Intraoperative transfusion was associated with increased postoperative length of stay (p = 0.03). Open procedure, operative time, estimated blood loss, intraoperative transfusion, and complications were not associated with timing of surgery.

Conclusions: Patients with hematologic malignancies can safely undergo cholecystectomy. Length of postoperative stay for inpatients is associated with intraoperative blood transfusion.

Keywords: Bone marrow transplant; Cholecystectomy; Hematologic malignancy.

MeSH terms

  • Acute Disease
  • Cholecystectomy / methods
  • Cholecystectomy, Laparoscopic* / methods
  • Cholecystitis* / complications
  • Cholecystitis* / pathology
  • Cholecystitis* / surgery
  • Cholecystitis, Acute* / surgery
  • Hematologic Neoplasms* / complications
  • Hematologic Neoplasms* / surgery
  • Humans
  • Length of Stay
  • Postoperative Complications / epidemiology
  • Postoperative Complications / surgery
  • Retrospective Studies
  • Treatment Outcome